Preoperative therapy: What, when and for whom?

Annals of Oncology

Volumn 19, Issue SUPPL. 5, 2008, Pages

  von Minckwitz, G ^a,b  

^a GBG Forschungs GmbH   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADD ON THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG WITHDRAWAL; EARLY CANCER; ECHOGRAPHY; FOLLOW UP; HUMAN; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; PATIENT SELECTION; PRACTICE GUIDELINE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SYSTEMIC DISEASE; SYSTEMIC THERAPY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; BREAST TUMOR; FEMALE; PATHOLOGY; PREOPERATIVE CARE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREOPERATIVE CARE;

EID: 49049098336     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn323     Document Type: Conference Paper

References (23)

1. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst 2005; 97: 188-194.
2. Kaufmann M, Hortobagyi GN, Goldhirsch A et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update. J Clin Oncol 2006; 24: 1940-1949.
3. Eiermann W, Paepke S, Appfelstaedt J et al. Letrozole Neo-Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 2001; 12: 1505-1506.
4. Kaufmann M, von Minckwitz G, Smith R et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations. J Clin Oncol 2003; 21: 2600-2608.
5. Bear HD, Anderson S, Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21: 4165-4174.
6. von Minckwitz G, Blohmer JU, Raab G et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: The GEPARTRIO pilot study. Ann Oncol 2005; 16: 56-63.
7. Chen AM, Meric-BerPSTam F, Hunt KK et al. Breast conservation after neoadjuvant chemotherapy. Cancer 2005; 103: 689-695.
8. Chen AM, Meric-BerPSTam F, Hunt KK et al. Breast conservation after neoadjuvant chemotherapy: The MD Anderson Cancer Center experience. J Clin Oncol 2004; 22: 2303-2312.
9. Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
10. Wolmark N, Wang J, Mamounas E et al. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project 8-18. J Natl Cancer Inst Monogr 2001; 30: 96-102.
11. Bear HD, Anderson S, Smith RE et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24: 2019-2027.
12. van Minckwitz G, Kuemmel S, du Bois A et al. Individualized treatment strategies according to in vivo-chemosensitivity assessed by response after 2 cycles of neoadjuvant chemotherapy. Final results of the Gepartrio study of German breast group. Presented at the 29th Annual San Antonio Breast Cancer Symposium, December 14-17, 2006 Abstr 42.
13. Wolmark N. NCI Consensus Meeting on PST, Bethesda 2007 (oral communication).
14. von Minckwitz G, Raab G, Caputo A et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group. J Clin Oncol 2005; 23: 2676-2685.
15. Raab G, Kaufmann M, Schuette M et al. Preoperative doxorubicin/ cyclophosphamide followed by docetaxel (AC-Doc) versus dose-dense doxorubicin and docetaxel (Adoc) as preoperative treatment in operable breast cancer: First analysis of the event-free survival of the GeparDuo-Study. Breast Cancer Res Treat 2005; 94 (Suppl 1): Abstr 5047.
16. von Minckwitz G, Rezai M, Loibl S et al. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/ cyclophosphamide → docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study 'GeparQuattro'. Presented at the 30th Annual San Antonio Breast Cancer Symposium, December 13-16, 2007; Abstr 79.
17. Gianni L, Basega J, Eiermann W et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005; 11: 8715-8721.
18. Untch M, Konecny G, Moebus V et al. Significant improvement in disease free and overall survival with neoadjuvant, dose intensified two weekly treatment with anthracycline and taxane in primary breast cancer, including inflammatory disease. Fifty five months median follow-up results of a multicenter prospective randomised phase III AGO-trial. Presented at the 30th Annual San Antonio Breast Cancer Symposium, December 13-16, 2007; Abstr 5052.
19. von Minckwitz G, Blohmer JU, Raab G et al. Comparison of docetaxel/ doxorubicin/cyclophosphamide (TAC) versus vinorelbine/capecitabine (NX) in patients non-responding to 2 cycles of neoadjuvant TAC chemotherapy - first results of the phase III GEPARTRIO-Study by the German Breast Group. Presented at the 28th Annual San Antonio Breast Cancer Symposium, December 8-11, 2005; Abstr 38.
20. von Minckwitz G, Blohmer J, Vogel P et al. Comparison of neoadjuvant 6 vs 8 cycles of docetaxel/doxorubicin/cyclophosphamide (TAC) in patients early responding to TACx2 - the GEPARTRIO Study. J Clin OnGol 2006; 24: 18S (Abstr 576).
21. German Arbeitsgemeinschaft Gynäkologische Onkologie guidelines on neoadjuvant breast cancer therapy. Available at: www.ago-online.org. Accessed 30.01.2008.
22. Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676-3685.
23. Gianni L, Semiglazov V, Manikhas GM et al. Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis. J Clin Oncol 2007; 25: 18 (Abstr 532).